These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 21518838

  • 1. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
    Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP.
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3220-5. PubMed ID: 21518838
    [Abstract] [Full Text] [Related]

  • 2. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
    Bhalodi AA, Crandon JL, Williams G, Nicolau DP.
    Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330
    [Abstract] [Full Text] [Related]

  • 3. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.
    Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM.
    J Antimicrob Chemother; 2010 Jul; 65(7):1428-32. PubMed ID: 20478991
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.
    Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP.
    Antimicrob Agents Chemother; 2012 May; 56(5):2576-80. PubMed ID: 22330908
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP.
    Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.
    Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, Black MT.
    J Antimicrob Chemother; 2009 Aug; 64(2):326-9. PubMed ID: 19493866
    [Abstract] [Full Text] [Related]

  • 15. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.
    Crandon JL, Nicolau DP.
    Antimicrob Agents Chemother; 2015 May; 59(5):2688-94. PubMed ID: 25712356
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.
    Stainton SM, Abdelraouf K, Utley L, Pucci MJ, Lister T, Nicolau DP.
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914941
    [Abstract] [Full Text] [Related]

  • 20. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).
    Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N.
    J Antimicrob Chemother; 2012 Jun; 67(6):1354-8. PubMed ID: 22441578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.